EW Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Edwards Lifesciences Corp (EW) is not a strong buy for a beginner investor with a long-term horizon at this moment. While the company has shown revenue growth, its significant decline in net income and EPS, coupled with neutral trading sentiment and lack of strong technical or proprietary trading signals, suggests waiting for better entry points.
The stock's MACD is negative and contracting (-0.278), RSI is neutral at 42.649, and moving averages are converging, indicating no clear trend. The stock is trading near its pivot level (82.833), with support at 81.026 and resistance at 84.64.
The company reported strong Q4 revenue growth (13.26% YoY), driven by TAVR momentum. Analysts like Piper Sandler and Goldman Sachs maintain positive long-term views, citing multiple growth drivers and strong business fundamentals.
Net income dropped significantly (-76.35% YoY), and EPS fell by -75.38% YoY. Analysts have lowered price targets recently, and trading sentiment from hedge funds and insiders is neutral. No recent news or congress trading data to act as catalysts.
In Q4 2025, revenue increased by 13.26% YoY to $1.57B, but net income dropped by -76.35% YoY to $91.2M. EPS fell by -75.38% YoY to $0.16, and gross margin slightly declined to 78.15%.
Analysts are mixed, with some lowering price targets (e.g., UBS to $90, Baird to $87, Truist to $89) and maintaining Neutral or Hold ratings. However, Piper Sandler and Goldman Sachs remain optimistic, with price targets of $100 and $95, respectively, and Buy/Overweight ratings.
